规格 | 价格 | 库存 | 数量 |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
STUDIES HAVE DEMONSTRATED THAT GALLAMINE IS EXCRETED IN DOG URINE AT RATE FASTER THAN OTHER MUSCLE RELAXANTS. .../IT/ DID NOT CROSS BLOOD-CEREBROSPINAL FLUID BARRIER. OTHER STUDIES...HAVE DETECTED GALLAMINE IN CEREBROSPINAL FLUID IN CONCN APPROACHING THOSE IN PLASMA DURING 1ST HR AFTER IV INJECTION. /GALLAMINE/ GALLAMINE IS ELIMINATED MAINLY BY RENAL EXCRETION... ... GALLAMINE CROSSES PLACENTAL BARRIER ... TRACE AMT OF GALLAMINE APPEARS IN FETUS 3 MIN AFTER ADMIN. /GALLAMINE, FROM TABLE/ For more Absorption, Distribution and Excretion (Complete) data for GALLAMINE TRIETHIODIDE (6 total), please visit the HSDB record page. Metabolism / Metabolites .../GALLAMINE/ IS UNMETABOLIZED. /GALLAMINE/ Biological Half-Life 135 minutes /From table/ |
---|---|
毒性/毒理 (Toxicokinetics/TK) |
Interactions
IN ANESTHETIZED PT, IV ADMIN OF DIAZEPAM MAY INCR INTENSITY & PROLONG DURATION OF NEUROMUSCULAR BLOCKADE PRODUCED BY GALLAMINE TRIETHIODIDE. CLINICAL REPORTS...ARE CONFLICTING.../&/ THERE ARE INSUFFICIENT DATA TO EXPLAIN POSSIBLE MECHANISM FOR GALLAMINE TRIETHIODIDE-DIAZEPAM INTERACTION. NEUROMUSCULAR BLOCKADE PRODUCED BY TUBOCURARINE WAS PROLONGED IN TWO THYROTOXIC PT RECEIVING HIGH DOSES (120 MG/DAY FOR 14 DAYS) OF PROPRANOLOL. ... ALTHOUGH THERE IS NO DOCUMENTATION, THE NONDEPOLARIZING MUSCLE RELAXANT GALLAMINE TRIETHIODIDE...ALSO SHOULD INTERACT WITH PROPRANOLOL. NEOMYCIN &...RELATED ANTIBIOTICS PRODUCE NEUROMUSCULAR TRANSMISSION FAILURE WHICH MAY CAUSE PROLONGED RESP DEPRESSION OR APNEA IN SURGICAL PT TREATED CONCURRENTLY WITH TUBOCURARINE &...NEUROMUSCULAR DEPRESSANTS. ...ADDITIVE NEUROMUSCULAR DEPRESSION.../REPORTED TO OCCUR WITH GALLAMINE TRIETHIODIDE/. QUINIDINE, ADMIN PARENTERALLY SHORTLY AFTER OR SIMULTANEOUSLY WITH TUBOCURARINE, MAY ENHANCE OR CAUSE RECURRENT NEUROMUSCULAR EFFECTS OF TUBOCURARINE, RESULTING IN PROLONGATION OR INTENSIFICATION OF RESP DEPRESSION & APNEA. ... GALLAMINE TRIETHIODIDE...HAS BEEN SHOWN TO INTERACT WITH QUINIDINE IN ANIMALS. For more Interactions (Complete) data for GALLAMINE TRIETHIODIDE (25 total), please visit the HSDB record page. Non-Human Toxicity Values LD50 Rat ip 23,200 ug/kg LD50 Rat sc 28,500 ug/kg LD50 Rat iv 5100 ug/kg LD50 Rat intraduodenal 380 mg/kg For more Non-Human Toxicity Values (Complete) data for GALLAMINE TRIETHIODIDE (13 total), please visit the HSDB record page. |
参考文献 |
J Pharmacol Exp Ther.1986 Jan;236(1):219-23.
|
其他信息 |
A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198) Drug Indication For use as adjuncts to anesthesia to induce skeletal muscle relaxation and to facilitate the management of patients undergoing mechanical ventilation Mechanism of Action It competes with acetylcholine (ACh) molecules and binds to muscarinic acetylcholine receptors on the post-synaptic membrane of the motor endplate. It acts by combining with the cholinergic receptor sites in muscle and competitively blocking the transmitter action of acetylcholine. It blocks the action of ACh and prevents activation of the muscle contraction process. It can also act on nicotinic presynaptic acetylcholine receptors which inhibits the release of ACh. GALLAMINE TRIETHIODIDE...PRODUCES SKELETAL MUSCLE RELAXATION BY COMBINING WITH RECEPTOR SITE AT NEUROMUSCULAR JUNCTION & BLOCKING ACTION OF NEUROTRANSMITTER ACETYLCHOLINE. IN RAT PHRENIC NERVE-DIAPHRAGM GALLAMINE HAD NO SIGNIFICANT EFFECTS ON ELECTROGENIC PROPERTIES OF EXCITABLE MEMBRANES OF MOTOR NERVE TERMINALS & MUSCLE FIBERS; IT DEPRESSED RESPONSE OF POSTSYNAPTIC RECEPTORS TO ACTION OF ACETYLCHOLINE. AT NEUROMUSCULAR JUNCTIONS IN MICE AND FROGS, FOLLOWING STEP CHANGES OF MEMBRANE POTENTIAL FROM -70 TO -130 MV, GALLAMINE (5 UMOL) IN THE PRESENCE OF ACETYLCHOLINE (3 UMOL) CAUSED AN INITIAL RAPID DECR IN CURRENT FOLLOWED BY OPENING OF CHANNELS AT A SLOWER RATE THAN WITH ACETYLCHOLINE ALONE. WHEN THE INTERNAL POTENTIAL WAS REDUCED TO -70 MV, THERE WAS A RAPID INCR IN CURRENT AT FIRST, FOLLOWED BY THE USUAL DECR WHICH WAS AGAIN SLOWER THAN NORMAL. THUS, GALLAMINE MAY PRODUCE A POTENTIAL-DEPENDENT BLOCK OF OPEN ION CHANNELS. Therapeutic Uses Neuromuscular Nondepolarizing Agents; Nicotinic Antagonists A NEUROMUSCULAR BLOCKING DRUG SIMILAR IN ITS ACTIONS & USES TO TUBOCURARINE CHLORIDE. ...IN GENERAL, IT HAS VERY LITTLE ACTION ON AUTONOMIC GANGLIA, BUT IT USUALLY BLOCKS CARDIAC VAGUS... IT ALSO DOES NOT RELEASE HISTAMINE /IN LOW DOSES/. ... IT HAS NO PERCEPTIBLE EFFECT ON NEWBORN INFANTS WHEN USUAL DOSES ARE GIVEN FOR CESAREAN SECTION & VAGINAL DELIVERY & TONE OF UTERUS IS NOT AFFECTED. ...HAS BEEN REPORTED TO REDUCE OCULAR PRESSURE SLIGHTLY IN PT. For more Therapeutic Uses (Complete) data for GALLAMINE TRIETHIODIDE (9 total), please visit the HSDB record page. Drug Warnings THE NEUROMUSCULAR BLOCKING AGENTS ARE POTENTIALLY HAZARDOUS DRUGS. ... THEY SHOULD BE ADMINISTERED TO PATIENTS ONLY BY ANESTHESIOLOGISTS & OTHER CLINICIANS WHO HAVE HAD EXTENSIVE TRAINING IN THEIR USE & IN A SETTING WHERE FACILITIES FOR RESPIRATORY & CARDIOVASCULAR RESUSCITATION ARE IMMEDIATELY AT HAND. /NEUROMUSCULAR BLOCKING AGENTS/ IT SHOULD BE USED CAUTIOUSLY IF TACHYCARDIA PREEXISTS. .../SINCE IT/ IS ELIMINATED MAINLY BY RENAL EXCRETION...ITS ACTION MAY BE PROLONGED IF THERE IS RENAL DYSFUNCTION. ... /IT SHOULD NOT/ BE USED IN PT WITH RENAL DISEASE. CROSS SENSITIVITY BETWEEN ALCURONIUM & D-TUBOCURARINE OCCURS & SIMILAR SITUATION MAY EXIST FOR SUXAMETHONIUM & GALLAMINE. For more Drug Warnings (Complete) data for GALLAMINE TRIETHIODIDE (6 total), please visit the HSDB record page. Pharmacodynamics Gallamine Triethiodide is a nondepolarizing neuromuscular blocking drug (NDMRD) used as an adjunct to anesthesia to induce skeletal muscle relaxation. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. Muscle groups differ in their sensitivity to these types of relaxants with ocular muscles (controlling eyelids) being most sensitive, followed by the muscles of the neck, jaw, limbs and then abdomen. The diaphragm is the least sensitive muscle to NDMRDs. Although the nondepolarizing neuromuscular blocking drugs do not have the same adverse effects as succinylcholine, their onset of action is slower. They also have a longer duration of action, making them more suitable for maintaining neuromuscular relaxation during major surgical procedures. |
分子式 |
C30H60I3N3O3
|
|
---|---|---|
分子量 |
891.53
|
|
精确质量 |
891.176
|
|
CAS号 |
65-29-2
|
|
相关CAS号 |
|
|
PubChem CID |
6172
|
|
外观&性状 |
White to yellow solid powder
|
|
密度 |
0.983g/cm3
|
|
沸点 |
502.6ºC at 760 mmHg
|
|
熔点 |
235ºC (dec.)
|
|
闪点 |
125.9ºC
|
|
折射率 |
1.501
|
|
tPSA |
27.69
|
|
氢键供体(HBD)数目 |
0
|
|
氢键受体(HBA)数目 |
6
|
|
可旋转键数目(RBC) |
21
|
|
重原子数目 |
39
|
|
分子复杂度/Complexity |
489
|
|
定义原子立体中心数目 |
0
|
|
InChi Key |
REEUVFCVXKWOFE-UHFFFAOYSA-K
|
|
InChi Code |
InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3
|
|
化学名 |
2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium triiodide
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意: 请将本产品存放在密封且受保护的环境中(例如氮气保护),避免吸湿/受潮和光照。 |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外实验) |
|
|||
---|---|---|---|---|
溶解度 (体内实验) |
配方 1 中的溶解度: 50 mg/mL (56.08 mM) in PBS (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液; 超声助溶。
请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.1217 mL | 5.6083 mL | 11.2167 mL | |
5 mM | 0.2243 mL | 1.1217 mL | 2.2433 mL | |
10 mM | 0.1122 mL | 0.5608 mL | 1.1217 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。